News from amgen inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Dec 17, 2014, 17:45 ET
Amgen Logo.

Amgen Announces 30 Percent Increase In 2015 First Quarter Dividend

 Amgen (NASDAQ: AMGN) today announced that its Board of Directors declared a $0.79 per share dividend for the first quarter of 2015. The...

Dec 11, 2014, 16:01 ET
Amgen Logo.

Amgen And AstraZeneca To Present Results From Phase 3 AMAGINE-1™ Study Evaluating Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis

Amgen (NASDAQ: AMGN) and AstraZeneca (NYSE: AZN) today announced that additional results from AMAGINE-1TM, a pivotal, multi-arm Phase 3 trial...

Dec 08, 2014, 21:00 ET
Amgen Logo.

Amgen Presents Data From Pivotal Phase 2 Study Of BLINCYTO™ (blinatumomab) Immunotherapy In Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

 Amgen (NASDAQ: AMGN) today announced that new data from a pivotal Phase 2 study evaluating BLINCYTO™ (blinatumomab) for the...

Dec 08, 2014, 16:20 ET
Amgen Logo.

New Trial Initiated Evaluating Amgen's Talimogene Laherparepvec In Combination With Merck's Anti-PD-1 Therapy KEYTRUDA® (Pembrolizumab) For Advanced Melanoma

Amgen (NASDAQ: AMGN) today announced the initiation of a trial of talimogene laherparepvec, an investigational oncolytic immunotherapy, in...

Dec 08, 2014, 14:47 ET
Amgen Logo. (PRNewsFoto/Amgen)

Amgen And Onyx Announce Detailed Results From Phase 3 ASPIRE Study Of Kyprolis® (Carfilzomib) In Patients With Relapsed Multiple Myeloma

 Amgen (NASDAQ: AMGN) and its subsidiary Onyx Pharmaceuticals, Inc., announced today results of the Phase 3 ASPIRE (CArfilzomib, Lenalidomide,...

Dec 08, 2014, 09:00 ET
Amgen Logo.

FDA Approves Amgen's XGEVA® (Denosumab) For The Treatment Of Hypercalcemia Of Malignancy Refractory To Bisphosphonate Therapy

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for XGEVA® (denosumab)...

Dec 06, 2014, 13:00 ET
Amgen Logo

Amgen Announces New Data From Phase 2 BLINCYTO™ (blinatumomab) Immunotherapy Study In Patients With Acute Lymphoblastic Leukemia And Minimal Residual Disease

 Amgen (NASDAQ:AMGN) today announced new data from the Phase 2 BLAST study which evaluated the bispecific T cell engager (BiTE®)...

Dec 03, 2014, 19:00 ET
Amgen Logo.

Amgen To Webcast Investor Meeting At Upcoming American Society of Hematology (ASH) 56th Annual Meeting And Exposition

Amgen (NASDAQ: AMGN) will host a webcast investor meeting at the American Society of Hematology (ASH) 56th Annual Meeting and Exposition on Monday,...

Dec 03, 2014, 16:45 ET

Actriz Adamari López y Amgen lanzan Quimioterapia: Mitos y Realidades sitio web y recursos en Español

Hoy Amgen (NASDAQ:AMGN) lanzo Quimioterapia: Mitos y Realidades, una extensión en Español de Chemotheraphy: Myths or Facts™,...

Dec 03, 2014, 16:30 ET
Amgen Logo.

Actress Adamari López And Amgen Launch Spanish-Language Chemotherapy: Myths Or Facts™ Website And Resources

Amgen (NASDAQ: AMGN) today launched Quimioterapia: Mitos y Realidades, a Spanish-language extension of the Chemotherapy: Myths or FactsTM awareness...

Dec 03, 2014, 15:48 ET
Amgen Logo

FDA Approves BLINCYTO™ (Blinatumomab) Immunotherapy for the Treatment of Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has granted approval of BLINCYTO™ (blinatumomab) for the...

Nov 25, 2014, 16:01 ET
Amgen Logo.

Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis

Amgen (NASDAQ: AMGN) and AstraZeneca (NYSE: AZN) today announced that AMAGINE-2TM, a pivotal, multi-arm Phase 3 trial evaluating two doses of...

Nov 24, 2014, 09:15 ET
Amgen Logo.

Amgen Announces Termination Of All Amgen-Sponsored Clinical Studies Of Rilotumumab In Advanced Gastric Cancer

 Amgen (NASDAQ:AMGN) today announced the termination of all Amgen-sponsored clinical studies of rilotumumab in advanced gastric cancer,...

Nov 18, 2014, 16:00 ET
Amgen Logo.

Amgen Presents Long-Term Data Showing Efficacy And Safety Of Investigational Cholesterol-Lowering Medication Evolocumab Across Lipid And LDL-C Levels

Amgen (NASDAQ:AMGN) today announced new data from three separate analyses of Phase 2 and 3 studies evaluating evolocumab, a novel investigational...

Nov 14, 2014, 16:15 ET
Amgen Logo.

Amgen To Present At The Jefferies Global Healthcare Conference

Amgen (NASDAQ: AMGN) will participate at the Jefferies Global Healthcare Conference on Wednesday, Nov. 19, 2014, in London, beginning at 8:40 a.m....

Nov 12, 2014, 16:35 ET
Amgen Logo.

Amgen To Webcast Investor Call At Upcoming American Heart Association Scientific Sessions

Amgen (NASDAQ:AMGN) will host a webcast call for the investment community at the American Heart Association (AHA) Scientific Sessions 2014 on...

Nov 12, 2014, 16:01 ET
Amgen Logo

Amgen To Highlight New Data For Investigational Cholesterol-Lowering Medication Evolocumab

Amgen (NASDAQ:AMGN) today announced that it will present 13 abstracts at the upcoming American Heart Association (AHA) Scientific Sessions 2014...

Nov 12, 2014, 09:00 ET
Amgen Scholars Program Expands To 17 Top Educational Institutions Worldwide

The Amgen Foundation Expands Amgen Scholars Program to 17 Top Educational Institutions Worldwide

 The Amgen Foundation today announced that the Amgen Scholars Program is expanding its presence with new host institutions in the U.S., Europe,...

Nov 11, 2014, 16:01 ET
Amgen Logo.

Amgen And AstraZeneca Announce Positive Results From Second Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis

Amgen (NASDAQ: AMGN) and AstraZeneca (NYSE: AZN) today announced that AMAGINE-3TM, a pivotal, multi-arm Phase 3 trial evaluating two doses of...

Nov 10, 2014, 09:15 ET
Amgen Logo.

FDA Accepts Amgen's Biologics License Application For LDL Cholesterol-Lowering Medication Evolocumab

Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Amgen's Biologics License Application...